Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INSIST

Financiado

IN Silico trials for treatment of acute Ischemic STroke

Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The mai... ver más

30/04/2022

Academisch Medisch...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

SC1-PM-16-2017: In-silico trials for developing and...

I+D

Cerrada hace 7 años

0% 95% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

Academisch Medisch Centrum A...

908.09K€ | Lider

MANUFACTURAS METALICAS CANAL...

601.71K€ | Participante

UvA

545.75K€ | Participante

UOXF

568.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 54 meses Fecha Inicio: 2017-10-16
Fecha Fin: 2022-04-30

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The main goal of INSIST is to advance treatments of ischemic stroke and its introduction in clinical practice by realizing in silico clinical stroke trials in which stroke and treatment are modeled. We will generate virtual populations of stroke patients, generate and validate in silico models for intra-arterial thrombectomy, thrombosis and thrombolysis, and microvascular perfusion and neurological deterioration after stroke, and integrate the in silico models to realize an in silico clinical stroke trial. We are uniquely positioned by the availability of a large pool of clinical, imaging, histopathological, and outcome data from multiple recently finalized stroke trials, a large registry (totaling 4500 patients), and new trials that will start later this year (totaling 2500 patients). We will build a population model that takes this input to generate virtual populations of stroke patients addressing the wide variety of patient characteristics. We will build on existing and emerging in silico models to validate reusable models for stroke and stroke treatment with a strong interaction with experimenting modeling in laboratories. The in silico models and virtual populations will be combined to simulate clinical trials and validated by simulating and comparing finalized and currently running trials. The in silico models will be used to simulate clinical trials to evaluate effectiveness and safety of novel devices and medication, both for the device as well as the pharmacological industry. For the device industry, we will evaluate the optimal configuration of thrombectomy stents for reduction of thrombus fragmentation. From the perspective of the pharmacy industry, we will simulate the effect of increased TAFIa on the effectiveness of alteplase.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores